Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.57 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.57 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MPO | P05164 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2334192 | 0.98 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2D6CYP2C19PLOD2 | |
| Hydrochloric Acid SCHEMBL4872565 | 0.98 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2D6CYP2C19PLOD2 | |
| Trifluoroacetic Acid SCHEMBL30436984 | 0.87 | PLOD2 (0.59) | CYP1A2CYP3A4CYP2D6CYP2C19PLOD2 | |
| SCHEMBL16404441 | 0.82 | CYP1A2 (0.59) | CYP1A2CYP3A4CYP2D6CYP2C19PLOD2 | |
| SCHEMBL15988710 | 0.80 | CYP2C19 (0.61) | CYP1A2CYP3A4CYP2D6CYP2C19PLOD2 | |
| SCHEMBL10948430 | 0.80 | PLOD2 (0.83) | CYP1A2CYP3A4CYP2D6CYP2C19PLOD2 | |
| Hydrochloric Acid SCHEMBL13738814 | 0.79 | GSK3B (0.42) | CYP3A4ALDH1A1HPGDHIF1AKDM4E | |
| SCHEMBL6461274 | 0.78 | PLOD2 (0.59) | CYP1A2CYP3A4CYP2D6CYP2C19PLOD2 | |
| SCHEMBL5163555 | 0.77 | CYP3A4 (0.64) | CYP1A2CYP3A4CYP2D6CYP2C19PLOD2 | |
| SCHEMBL3108729 | 0.77 | PLOD2 (0.64) | CYP1A2CYP3A4CYP2D6CYP2C19PLOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312580-A1 | 1-(5-(2-CYANOPYRIDIN-4-YL)OXAZOLE-2-CARBONYL)-4-METHYLHEXAHYDROPYRROLO[3,4-B]PYR ROLE-5(1H)-CARBONITRILE AS USP30 INHIBITOR FOR USE IN THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION, CANCER AND FIBROSIS | MISSION THERAPEUTICS LIMITED (GB) | 2023-10-05 | — | — | US | disclosed |
| US-20230312580-A1 | 1-(5-(2-CYANOPYRIDIN-4-YL)OXAZOLE-2-CARBONYL)-4-METHYLHEXAHYDROPYRROLO[3,4-B]PYR ROLE-5(1H)-CARBONITRILE AS USP30 INHIBITOR FOR USE IN THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION, CANCER AND FIBROSIS | MISSION THERAPEUTICS LIMITED (GB) | 2023-10-05 | — | — | US | disclosed |
| US-11773109-B2 | Composition for hardening soft tissue | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION | 2023-10-03 | — | — | US | disclosed |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230151396-A1 | METHOD FOR SYNTHESIZING A CHIRAL DIAMINE COMPOUND | ASYMCHEM LABORATORIES (TIANJIN) CO., LTD. (CN) | 2023-05-18 | — | — | US | disclosed |
| US-20230151396-A1 | METHOD FOR SYNTHESIZING A CHIRAL DIAMINE COMPOUND | ASYMCHEM LABORATORIES (TIANJIN) CO., LTD. (CN) | 2023-05-18 | — | — | US | disclosed |
| US-20230142405-A1 | A CONTINUOUS FLOW SYNTHESIS METHOD FOR THE MANUFACTURE OF ISONIAZID | Nelson Mandela University (ZA) | 2023-05-11 | — | — | US | disclosed |
| US-20230134587-A1 | BIOMARKER TESTING AND DIAGNOSTICS | UNIVERSITY OF WASHINGTON | 2023-05-04 | — | — | US | disclosed |
| EP-4161929-A1 | 1-(5-(2-CYANOPYRIDIN-4-YL)OXAZOLE-2-CARBONYL)-4-METHYLHEXAHYDROPYRROLO[3,4-B]PYR ROLE-5(1H)-CARBONITRILE AS USP30 INHIBITOR FOR USE IN THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION, CANCER AND FIBROSIS | Mission Therapeutics Limited (GB) | 2023-04-12 | — | — | EP | disclosed |
| CN-115836073-A | 1- (5- (2-cyanopyridin-4-yl) oxazole-2-carbonyl) -4-methylhexahydropyrrolo [3,4-B ] pyrrole-5 (1H) -carbonitrile as a USP30 inhibitor for the treatment of mitochondrial dysfunction, cancer and fibrosis | 特殊治疗有限公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-0653421-B1 | Process for preparing 2-cyanoimidazole compounds | ISHIHARA SANGYO KAISHA (JP) | 1997-01-15 | — | — | EP | disclosed |
| US-5552557-A | Process for preparing 2-cyanoimidazole compounds by reaction of an amino ketone compound | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1996-09-03 | — | — | US | disclosed |
| EP-0507650-B1 | Piperidine derivatives, their preparation and their therapeutic application | SYNTHELABO (FR) | 1996-05-22 | — | — | EP | disclosed |
| EP-0653421-A1 | Process for preparing 2-cyanoimidazole compounds | ISHIHARA SANGYO KAISHA LTD. (JP) | 1995-05-17 | — | — | EP | disclosed |
| EP-0507650-A1 | Piperidine derivatives, their preparation and their therapeutic application | SYNTHELABO (FR) | 1992-10-07 | — | — | EP | disclosed |
| US-5106986-A | PREPARATION OF AMINOETHANOL DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1992-04-21 | — | — | US | disclosed |
| EP-0450180-A2 | Process for the preparation of aminoethanol derivatives | BAYER AG (DE) | 1991-10-09 | — | — | EP | disclosed |
| EP-0051371-B1 | IMIDAZOLYLPYRIDINE THERAPEUTIC AGENTS | PFIZER INC. (US) | 1984-08-29 | — | — | EP | disclosed |
| EP-0051371-A2 | Imidazolylpyridine therapeutic agents | PFIZER INC. (US) | 1982-05-12 | — | — | EP | disclosed |
| US-4302464-A | ANTIULCER AGENTS, ANTI-H2-HISTAMINES | PFIZER INC. (US) | 1981-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773109-B2 | Composition for hardening soft tissue | PNLIP, AMY2A, RNASE1 | CYP1A2 4782/4885CYP3A4 4739/4885CYP2D6 4796/4885 |
| US-20230312580-A1 | 1-(5-(2-CYANOPYRIDIN-4-YL)OXAZOLE-2-CARBONYL)-4-METHYLHEXAHYDROPYRROLO[3,4-B]PYR ROLE-5(1H)-CARBONITRILE AS USP30 INHIBITOR FOR USE IN THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION, CANCER AND FIBROSIS | USP30, USP1, USP28 | CYP1A2 2077/4885CYP3A4 2071/4885CYP2D6 3744/4885 |
| US-20230159455-A1 | DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS | PNMT, HNMT, NNMT | CYP1A2 313/4885CYP3A4 347/4885CYP2D6 316/4885 |
| US-20230142405-A1 | A CONTINUOUS FLOW SYNTHESIS METHOD FOR THE MANUFACTURE OF ISONIAZID | IDH1, IDH2, IMPDH2 | CYP1A2 176/4885CYP3A4 69/4885CYP2D6 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.